Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell | 4 studies | 21% ± 1% | |
| glutamatergic neuron | 4 studies | 43% ± 12% | |
| astrocyte | 4 studies | 24% ± 6% | |
| classical monocyte | 3 studies | 25% ± 6% | |
| microglial cell | 3 studies | 21% ± 0% | |
| GABAergic neuron | 3 studies | 42% ± 7% | |
| macrophage | 3 studies | 16% ± 1% | |
| interneuron | 3 studies | 41% ± 22% | |
| neuron | 3 studies | 24% ± 5% | |
| oligodendrocyte | 3 studies | 21% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 5 studies | 33% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 2766.17 | 1445 / 1445 | 100% | 17.86 | 183 / 183 |
| prostate | 100% | 3818.73 | 245 / 245 | 100% | 17.35 | 502 / 502 |
| thymus | 100% | 2906.51 | 653 / 653 | 100% | 11.97 | 604 / 605 |
| breast | 100% | 2827.90 | 459 / 459 | 100% | 16.61 | 1116 / 1118 |
| skin | 100% | 3500.70 | 1809 / 1809 | 100% | 16.71 | 471 / 472 |
| brain | 100% | 3571.76 | 2640 / 2642 | 100% | 18.62 | 704 / 705 |
| uterus | 100% | 3461.40 | 170 / 170 | 100% | 12.87 | 457 / 459 |
| intestine | 100% | 3288.68 | 966 / 966 | 99% | 10.72 | 523 / 527 |
| bladder | 100% | 3311.43 | 21 / 21 | 99% | 11.64 | 500 / 504 |
| lung | 100% | 3161.25 | 578 / 578 | 99% | 14.29 | 1144 / 1155 |
| stomach | 100% | 2402.62 | 359 / 359 | 99% | 13.27 | 282 / 286 |
| pancreas | 100% | 1784.30 | 327 / 328 | 99% | 10.28 | 176 / 178 |
| ovary | 100% | 3245.46 | 180 / 180 | 98% | 14.36 | 423 / 430 |
| adrenal gland | 100% | 3931.22 | 258 / 258 | 97% | 9.52 | 222 / 230 |
| kidney | 100% | 2048.73 | 89 / 89 | 96% | 11.45 | 866 / 901 |
| liver | 98% | 1177.95 | 221 / 226 | 82% | 5.55 | 332 / 406 |
| adipose | 100% | 2721.95 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 3334.87 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 11.76 | 29 / 29 |
| spleen | 100% | 3956.80 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 13.90 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 6.67 | 1 / 1 |
| muscle | 100% | 1646.30 | 802 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 99% | 9.68 | 79 / 80 |
| heart | 98% | 2014.79 | 848 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 97% | 2907.81 | 905 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0035196 | Biological process | miRNA processing |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0090625 | Biological process | siRNA-mediated gene silencing by mRNA destabilization |
| GO_0035279 | Biological process | miRNA-mediated gene silencing by mRNA destabilization |
| GO_0035278 | Biological process | miRNA-mediated gene silencing by inhibition of translation |
| GO_0031054 | Biological process | pre-miRNA processing |
| GO_0016525 | Biological process | negative regulation of angiogenesis |
| GO_0035194 | Biological process | regulatory ncRNA-mediated post-transcriptional gene silencing |
| GO_0070922 | Biological process | RISC complex assembly |
| GO_0010501 | Biological process | RNA secondary structure unwinding |
| GO_0000956 | Biological process | nuclear-transcribed mRNA catabolic process |
| GO_0070578 | Cellular component | RISC-loading complex |
| GO_0036464 | Cellular component | cytoplasmic ribonucleoprotein granule |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0000932 | Cellular component | P-body |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0016442 | Cellular component | RISC complex |
| GO_0005634 | Cellular component | nucleus |
| GO_0004521 | Molecular function | RNA endonuclease activity |
| GO_0001046 | Molecular function | core promoter sequence-specific DNA binding |
| GO_0003727 | Molecular function | single-stranded RNA binding |
| GO_0000993 | Molecular function | RNA polymerase II complex binding |
| GO_0003723 | Molecular function | RNA binding |
| GO_0035198 | Molecular function | miRNA binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0003725 | Molecular function | double-stranded RNA binding |
| Gene name | AGO1 |
| Protein name | Protein argonaute-1 (Argonaute1) (hAgo1) (Argonaute RISC catalytic component 1) (Eukaryotic translation initiation factor 2C 1) (eIF-2C 1) (eIF2C 1) (Putative RNA-binding protein Q99) Argonaute RISC component 1 |
| Synonyms | EIF2C1 |
| Description | FUNCTION: Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) or short interfering RNAs (siRNAs), and represses the translation of mRNAs which are complementary to them. Lacks endonuclease activity and does not appear to cleave target mRNAs. Also required for transcriptional gene silencing (TGS) of promoter regions which are complementary to bound short antigene RNAs (agRNAs). . |
| Accessions | ENST00000699843.1 ENST00000674426.1 ENST00000373206.5 Q9UL18 A0A6I8PTZ8 A0A8V8TNY0 A0A8V8TQA7 ENST00000699841.1 ENST00000699842.1 Q5TA58 ENST00000373204.6 A0A8V8TPF2 A0A8V8TQN5 ENST00000635259.1 ENST00000699844.1 A0A0U1RQZ8 |
